Search the Newsreel

Assenagon Asset Management S.A. Has $69.25 Million Position in Amgen Inc. $AMGN

Assenagon Asset Management S.A. significantly reduced its stake in Amgen Inc. by 44.5% during the second quarter, now holding 191,247 shares valued at $69.25 million. Despite this, other institutional investors have increased their positions, and analysts have set new price targets, with a consensus …

Iamgold (NYSE:IAG) Downgraded by Wall Street Zen to "Hold"

Wall Street Zen has downgraded Iamgold (NYSE:IAG) to a "Hold" rating, moving it from a "Buy." Despite this, the broader analyst consensus for Iamgold remains a "Moderate Buy" with an average price target of $19.00. The company reported quarterly EPS of $0.42, matching estimates, …

IAMGOLD Corporation (NYSE: IAG) lifts Q2 2026 cash, cuts debt and buys back shares

IAMGOLD Corporation announced strong Q2 2026 results, reporting increased revenues, net earnings, and adjusted EBITDA, driven by higher gold prices and production. The company strengthened its balance sheet by fully repaying its credit facility, repurchasing 8.6 million shares for $147.9 million, and increasing liquidity …

Affiliated Managers Group (AMG) Q1 2024 Earnings Report - Results, Call & Slides

Affiliated Managers Group (AMG) Q1 2026 Earnings Report - Results, Call & Slides

Amgen SVP & CCO Nancy Grygiel disposes of $1.19m in stock

Amgen's SVP & CCO, Nancy A. Grygiel, sold approximately $1.19 million worth of Amgen stock on August 6, 2026. This transaction was related to the exercise of non-qualified stock options, with the sales primarily covering the exercise price and withholding taxes. Following these transactions, …

Iamgold Corp (IAG) (Q2 2026) Earnings Call Highlights: Record Cash Flow and Strategic Expansion ...

This article first appeared on GuruFocus. Release Date: August 07, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Iamgold Corp (NYSE:IAG) produced 188,100 ounces of gold in Q2 2026, bringing year-to-date production to …

Trade Tracker: Kevin Simpson buys more Amgen

Kevin Simpson, founder and CIO of Capital Wealth Planning, has increased his holdings in Amgen. He discussed his rationale for buying more shares at current price levels during an appearance on CNBC's 'Halftime Report.' The article primarily features a video clip of his explanation.

IAMGOLD Corporation 2026 Q2 - Results - Earnings Call Presentation (TSX:IMG:CA) 2026-08-07

Amgen Inc. $AMGN Shares Acquired by Czech National Bank

The Czech National Bank increased its stake in Amgen Inc. by 4.8% in the second quarter, acquiring an additional 6,969 shares and bringing its total holdings to 153,622 shares valued at $55.6 million. This comes as Amgen reported strong second-quarter results, exceeding analyst expectations …

PensionDanmark Pensionsforsikringsaktieselskab Grows Stake in Amgen Inc. $AMGN

PensionDanmark Pensionsforsikringsaktieselskab increased its stake in Amgen Inc. by 12.3% in the second quarter, bringing its total ownership to 108,300 shares valued at approximately $39.2 million. This comes as Amgen reported strong quarterly results, with a 9.5% revenue increase and raised 2026 adjusted EPS …

Pfizer, Merck, Amgen Double Down On Cancer And Send Takeover Buzz Around SLS And IBRX Into Overdrive

Pfizer, Merck, and Amgen are expanding their cancer portfolios, leading to increased speculation about smaller oncology companies like Sellas Life Sciences (SLS) and ImmunityBio (IBRX) being potential acquisition targets. Pfizer's Seagen portfolio and Padcev, Merck's sac-TMT, and Amgen's T-cell engagers and Imdelltra are key …

IAMGOLD Corp. (IAG) Misses Q2 EPS by 12c

IAMGOLD Corp. (IAG) reported its Q2 earnings, missing analyst expectations for both EPS and revenue. The company posted an EPS of $0.42, which was $0.12 lower than the estimated $0.54, and revenue came in at $856.9 million against a consensus estimate of $932.83 million.

IAMGOLD Non-GAAP EPS of $0.42 misses by $0.02, revenue of $856.9M misses by $21.21M

* IAMGOLD press release [https://seekingalpha.com/filing/309923403] (IAG [https://seekingalpha.com/symbol/IAG]): Q2 Non-GAAP EPS of $0.42 misses by $0.02. * Revenue of $856.9M (+47.5% Y/Y) misses by $21.21M. * Attributable gold production was 188,100 ounces in the second quarter and 371,700 ounces year-to-date (“YTD”), with the Company on …

IAMGOLD appoints Catherine McLeod-Seltzer to board

IAMGOLD Corporation has announced that Catherine McLeod-Seltzer will join its board of directors on September 1, 2026. McLeod-Seltzer brings over 40 years of mining industry experience, including executive roles and board memberships at companies like Teck Resources Limited and Kinross Gold Corporation. Her extensive …

IAMGOLD Reports Second Quarter 2026 Results

All monetary amounts are expressed in U.S. dollars, unless otherwise indicated. Toronto, Ontario--(Newsfile Corp. - August 6, 2026) - IAMGOLD Corporation (NYSE: IAG) (TSX: IMG) ("IAMGOLD" or the "Company") today reported its financial and operating results for the second quarter ended June 30, 2026. …

IAMGOLD Announces Appointment of Catherine McLeod-Seltzer to the Board of Directors

All monetary amounts are expressed in U.S. dollars, unless otherwise indicated. Toronto, Ontario--(Newsfile Corp. - August 6, 2026) - IAMGOLD Corporation (TSX: IMG) (NYSE: IAG) ("IAMGOLD" or the "Company") today announced that Ms. Catherine McLeod-Seltzer has been appointed to the Company's board of directors …

IAMGold earnings up next: Can margins hold amid gold retreat?

IAMGold Corporation is preparing to report its second-quarter earnings, with investors focused on whether the gold miner can maintain strong profit margins despite a significant retreat in gold prices. Analysts anticipate earnings of 50 cents per share on $932.8 million in revenue, a sequential …

Amgen separates from weak drugmaker group, but 31% fair-value gap raises the bar

AMGN added 2.4% in the week to 31 July and sits only 3.2% below its 52-week high, with the Trend Signal active but volume confirmation still modest.

Trilogy Capital Inc. Has $302,000 Stock Holdings in Amgen Inc. $AMGN

Trilogy Capital Inc. significantly reduced its stake in Amgen Inc. by 91.8% in the second quarter, now holding 833 shares valued at approximately $302,000. Despite this, Amgen exceeded second-quarter expectations with adjusted earnings of $6.29 per share and revenue of $10.05 billion, and announced …

Amgen (AMGN) Stock Jumps As Raised Guidance Meets Mounting Risks

Amgen's stock jumped by 5% after its Q2 2026 earnings report, with revenue exceeding US$10 billion and basic EPS above US$4, leading to lifted full-year guidance. While new drugs and biosimilars are driving growth, the company faces significant risks including regulatory issues, product concentration, …

Iamgold (IAG) Earnings Date and Reports 2026 $IAG

Amgen Inc (AMGN) (Q2 2026) Earnings Call Highlights: Revenue Surges Past $10 Billion, Guidance ...

Amgen Inc. reported strong Q2 2026 earnings with total revenues exceeding $10 billion, a 10% year-over-year increase, driven by double-digit sales growth in 22 products and significant contributions from key growth drivers like Repatha, EVENITY, and TEZSPIRE. The company also raised its 2026 revenue …

A Look at Amgen Inc (AMGN) After 4.6% Gain -- GF Value $353.96 v

Amgen Inc. (AMGN) shares recently rose 4.6% to $407.83, significantly above its GF Value™ of $353.96, indicating the stock is 15.2% overvalued. Despite a strong GF Score™ of 80/100, driven by high profitability and growth, its low momentum and financial strength rankings, alongside a …

AMG Critical Materials (ENXTAM:AMG) Stock Looks Near Fair Value After 35% Gain

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. AMG Critical Materials stock has returned 35.0% over the past year, and after that …

Amgen (NASDAQ:AMGN) Stock Price Expected to Rise, TD Cowen Analyst Says

TD Cowen has raised its price target for Amgen (NASDAQ:AMGN) to $452 from $420, maintaining a "Buy" rating and suggesting an 11.3% upside. This comes after Amgen exceeded Q2 earnings expectations with EPS of $6.29 and revenue of $10.05 billion, driven by newer products, …

Amgen Inc Stock (AMGN) Moved Up by 4.57% on Aug 5: Drivers Behind the Movement

Amgen Inc. (AMGN) saw its stock rise by 4.57% on August 5th, driven by a strong quarterly earnings report that surpassed expectations and increased full-year guidance. Positive clinical trial updates for its obesity drug MariTide also boosted investor confidence, with analysts raising price targets …

Amgen Extends Obesity Trial, Sharpening Its Long-Term Weight-Loss Bet

Amgen Inc. announced an update on its Phase 3 MARITIME-1-EXTENSION study for its obesity drug, maridebart cafraglutide (AMG 133 or MariTide). The trial aims to assess the long-term efficacy and safety of the drug in helping obese or overweight individuals maintain weight loss and …

Where Does Affiliated Managers Group (AMG) Valuation Sit Following Strong Q2 Earnings?

Amgen stock hits all-time high at 398.65 USD

Amgen Inc. stock has reached an all-time high of $398.65, currently trading at $403.13, giving the biotechnology giant a market capitalization of $210.5 billion. The surge reflects investor confidence following strong performance, with the stock price increasing by 37.01% over the past year and …

Amgen (AMGN) Could Be 8% Overvalued Following Raised 2026 Guidance

Amgen (AMGN) reported strong Q2 2026 results, beating analyst expectations and raising its full-year revenue and earnings guidance. Despite a significant share price increase, Simply Wall St's narrative valuation suggests the stock is 8.3% overvalued at $390.02, with a fair value of $359.98, while …

Amgen gains after strong quarterly results and continued product momentum

Amgen's shares rose approximately 4% after the biotechnology company announced second-quarter 2026 results that exceeded Wall Street expectations. The company reported adjusted earnings per share of $6.29 and revenue of $10.05 billion, driven by a 10% year-over-year increase in total revenue and double-digit sales …

Affiliated Managers Group, Inc. Stock 12‑Month Price Target Raised to $434.29, Implies 14% Upside

Affiliated Managers Group, Inc. (AMG) has seen its average 12-month price target raised to $434.29 from $430 by 7 analysts, implying a 14% potential upside from its Aug. 3 closing price. The consensus rating among 8 analysts remains a "Buy," with forecasts ranging from …

Liberty Metals Appoints Former IAMGOLD President & CEO Steve Letwin as Non-Executive Director

Liberty Metals Limited (ASX:LIB) has appointed Steve Letwin, former President and CEO of IAMGOLD Corporation, as a Non-Executive Director, effective August 5, 2026. Mr. Letwin brings over four decades of experience in the global resources and energy sectors, including corporate finance, operational management, and …

AMGEN REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS

Amgen reported strong second-quarter 2026 financial results, with total revenues increasing 10% to $10.1 billion and product sales growing 9%, driven by volume. The company saw significant growth in several key products like Repatha, EVENITY, and TEPEZZA, and provided updates on its extensive pipeline, …

Amgen (AMGN) Lifted 2026 Guidance, Is The Valuation Still Too Rich?